Takeda plans further expansion in Russia

10 January 2019

Japanese drugmaker Takeda (TYO: 4502) has officially announced that it has invested more than 98 million euros (~$112 million) in the development of drug production in Russia during the 2010-2018 period, and is ready to continue its investment activities in the local market over the n ext several years, reports The Pharma Letter’s local correspondent.

Of these funds, about 477 million roubles ($7 million) were spent on the production of ixazomib, the innovative orphan drug for patients with multiple myeloma, which is marketed by Takeda as Ninlaro.

Takeda currently pins big hopes on this drug in the Russian market, of which is it is beginning production at its Yaroslavl plant shortly.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK